Radiation oncology firm Accuray has reported positive results from the clinical study of its Radixact System to treat different types of cancer with enhanced efficiency and accuracy.

The findings were presented at the 59th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Denver, Colorado, US, between 30 July and 3 August.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Radixact System is a smart radiation therapy that employs similar characteristics of the firm’s TomoTherapy treatment delivery.

With precision, this system enables clinicians to treat cancer cases from initial plan delivery to adaptive therapy and complex retreatments, while it also offers treatment speed and ease of use.

During the study, therapy plans created with Accuray Precision Treatment Planning System (TPS) for the Radixact were compared with those created using the VoLO Planning Solution for the TomoHDA system.

See Also:

"Plans developed using Accuray TPS were found to be comparatively faster with decreased beam-on time of around 50%."

Plans developed using Accuray TPS were found to be comparatively faster with decreased beam-on time of around 50%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The evaluation of Radixact low-dose fan beam MVCT image guidance did not show a statistically significant difference in the noise, uniformity and Hounsfield units (HU) stability over a period of three-months.

Upon assessment of beam characteristics for six months, Radixact data was found to be within the specifications determined for the TomoTherapy System, and indicated that the beam commissioning process will be straightforward.

Two studies were also performed to validate the feasibility of leveraging TomoTherapy System's helical delivery capabilities for real-time motion management.

Accuray vice-president and chief technology officer Calvin Maurer said: "The Radixact System findings reinforce what customers are experiencing in their day-to-day practice and demonstrate its value to the radiation oncology team and their patients.”